Low-to-intermediate-risk Prostate Carcinoma
1 clinical trials · Condition
◉ Watch Low-to-intermediate-risk Prostate Carcinoma
| Record | Firm | Date |
|---|---|---|
| Safety of Dose Escalation in Definitive Hypofractionated Radiation Therapy With SPACEOAR TM for Patients With Low-to-intermediate Risk Localized Prostate Cancer (DESAR-L) (NCT06461819) | Samsung Medical Center | 2023-08-11 |
Track Low-to-intermediate-risk Prostate Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.